Clinical Trial

Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma

Name: Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma — clinical trial record (NCT07477912)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MSTH-CAR001

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The mail purpose of this study is to estimate the safety and the efficacy of anti-BCMA CAR- T cell immunotherapy for adults with relapsed or refractory multiple myeloma

Trial Details

NCT Number	NCT07477912
Lead Sponsor	Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Conditions	Multiple Myeloma Refractory
Enrollment	30 participants
Start Date	2025-02-01
Primary Completion	2028-02-01 (estimated)
Study Completion	2030-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-17